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We report a novel pathomechanism for
membranoproliferative glomerulonephritis type II (MPGN II)
caused by a mutant Factor H protein expressed in the
plasma. Genetic analyses of two patients revealed deletion of
a single Lys residue (K224) located within the complement
regulatory region in domain 4 of Factor H. This deletion
resulted in defective complement control: mutant protein
purified from the plasma of patients showed severely
reduced cofactor and decay-accelerating activity, as well as
reduced binding to the central complement component C3b.
However, cell-binding activity of the mutant protein was
normal and comparable to wild-type Factor H. The patients
are daughters of consanguineous parents. As both patients
but also their healthy mother were positive for C3 nephritic
factor, the mutant Factor H protein is considered relevant for
unrestricted activation of the disease-causing activation of
the alternative complement pathway. Replacement of
functional Factor H by fresh frozen plasma (10–15 ml/kg/14
days) was well tolerated, prevented so far disease
progression in both patients, and is in the long run expected
to preserve kidney function.
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Membranoproliferative glomerulonephritis type II (MPGN
II), also termed dense deposit disease, is a rare disease, which
is characterized by complement containing dense deposits
within the basement membrane of the glomerular capillary
wall and followed by capillary wall thickening, mesangial cell
proliferation, and glomerular fibrosis.1,2 So far three distinct
scenarios, all of them leading to complement dysregulation,
have been linked to membranoproliferative glomerulo-
nephritis: absence of Factor H in plasma;3–11 the inactivation
of Factor H by a circulating inhibitor;12 and the presence of
the autoantibody C3 nephritic factor (C3NeF).13–15
The absence of Factor H in plasma as cause for MPGN II
has been observed in humans,2–11 pigs,16 and in mice.17 The
genetic defect leading to Factor H deficiency has been
analyzed in five patients, from four families. In a native
American, single-nucleotide mutations affect Cys residues
C518R of one and C941Y of the second allele.18 Factor H is
composed of 20 complement control protein (CCP)
modules, also known as short consensus repeats. The absence
of conserved framework Cys residues within CCP 9 and CCP
16 affects disulphide bond formation.18 Two members of
another family show homozygous mutations in CCP 2
(R127L), and the other individuals have either amino acid
exchange in CCP 7 (C431S) or in CCP 11 (C673S).11
Factor H deficient pigs represent natural mutants16 and
Factor H knockout mice were genetically designed.17
Deficient pigs display homozygous mutations of L493V and
I1166R located within CCP 9 and CCP 20.19 These non-
framework mutations result in a block of protein secretion.
The mutant protein is expressed, but retained in the
endoplasmic reticulum and accumulates in the cytoplasm.
In addition, the presence of C3NeF in plasma is also linked
to MPGN II, and between 54% of adult and 82% of pediatric
patients are positive for this autoantibody.15,20 However,
C3NeF is also observed in patients with partial lipid
dystrophy, menigococcal meningitis, and even in healthy
individuals.20 Both Factor H and C3NeF control the same
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enzyme, the alternative pathway convertase C3bBb. Factor H
dissociates the C3bBb complex and – together with Factor I –
inactivates the convertase. C3NeF, an immunoglobulin G
(IgG) or immunoglobulin M autoantibody, has an opposite
effect; it stabilizes the convertase and increases its half-life by
approximately 10-fold.13,21 Thus, quite distinct abnormalities
lead to continuous C3 activation, thereby causing damage of
the glomerular basement membrane.1,13 To our knowledge, a
combination of two disease-causing factors in one patient has
not yet been described.
We here report two MPGN II patients who express a
mutated, functionally defective Factor H protein, and are
positive for C3NeF. In the patients, the mutant Factor H
protein is secreted and shows a homozygous deletion of
Lys224 (K224), which is located within the complement
regulatory region in CCP 4. Mutant Factor H protein
purified from plasma of both patients showed defective
complement regulation. To our knowledge, this study reports
the first secreted, mutant Factor H protein in two MPGN II
patients that displays defective complement control.
RESULTS
Renal biopsy
Examination of renal biopsy specimens of patients A (two
biopsies at intervals of 5 years) and B (one biopsy) showed
typical findings of MPGN II (‘dense deposit disease’),
including thickening (light microscopy), deposition of C3c
and C5b-9 (immunohistology), and segmental osmiophilic
transformation of the glomerular basement membrane
(electron microscopy) (Figure 1).
Pedigree, complement profile, Factor H mobility, and
concentration
The two patients, daughters of consanguineous parents,
developed MPGN II at the age of five and one (Figure 2a).
Strong activation of both, the alternative and the classical
pathway of the complement (Table 1), was shown by
decreased C3 and Factor B levels, as well as by increased
C3d levels (Table 1). The two patients, their healthy mother,
but not their father, were positive for C3NeF. Following
separation of plasma by sodium dodecyl sulfate-polyacryla-
mide gel electrophoresis (SDS-PAGE) and Western blotting,
Factor H of the patients showed normal mobility and no
additional bands were detectable (Figure 2b, lanes 1 and 2).
Factor H concentration in both patients was slightly reduced
(224 and 254 mg/ml; normal: 284–428 mg/ml). Both parents
showed normal Factor H mobility (Figure 2b, lanes 3 and 4)
and their Factor H plasma levels were also in the lower
normal range; Factor I levels were normal (Table 1).
Genetic analysis of the Factor H gene
Genetic analysis of DNA derived from the two patients and
their parents revealed several nucleotide exchanges within the
Factor H gene (Figure 3 and Table 2). One is located in the
promoter region (C30081T), and a second results in a
deletion of three nucleotides (genomic DNA: 57 967–57 969;
cDNA: 743–745) and causes deletion of a Lys residue at
position 224 (K224) in CCP 4 (Figure 3). A third exchange in
CCP 5 (genomic DNA: C63488A; cDNA: C994A) is silent
(protein: A307A), and a fourth exchange in CCP 7 (genomic
DNA: C68401T; cDNA: C1277T) causes a His402Tyr
exchange (protein: H402Y). In addition, an exchange was
Figure 1 | Renal biopsy specimen of patient A (EM). Typical
findings of MPGN II (dense deposit disease) with thickening of the
glomerular basement caused by deposits within the lamina densa of
the glomerular basement membrane.
Table 1 | Complement profile in plasma of the two MPGN II
patients and their healthy parents
Patient A Patient B Father Mother
Age (years) 10 5 31 29
APH50 (80–120%) 34 11 116 121
CH50 (65–135%) 7 8 102 104
C3 (750–1400mg/ml) 196 120 820 710
Factor B (134–438mg/ml) 65 38 213 230
C3d (35–70 mU/l) 130 117 33 34
Factor H (284–528mg/ml) 224 254 205 268
Factor I (20–44 mg/ml) 36 30 25 33
C3 nephritic factor Positive Positive Negative Positive
APH50, functional activity of alternative; CH50, functional activity of classical; MPGN
II, membranoproliferative glomerulonephritis type II.
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Figure 2 | Pedigree of the family and detection of Factor H in
plasma of two MPGN II patients and their parents. (a) Pedigree of
the family. The two patients are 10- and 5-year-old daughters of
healthy consanguineous parents. Patient A developed MPGN II at age
of 5 and patient B showed signs of disease at age of 1 year.
(b) Detection of Factor H in the plasma of two MPGN II patients
and their parents. Plasma was separated by SDS-PAGE, transferred
onto a membrane, and assayed by Western blot using a Factor H
specific polyclonal antiserum.
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identified within the intronic region (2487–28A/C) between
CCPs 13 and 14.
The mother and the father are both heterozygous for the
mutation in CCP 4. On the basis of distribution of the base
exchanges in the genome of her children, the mutations can
be linked within the two alleles of the mother. The mutation
in CCP 4, and the exchange in the intronic region spanning
CCP modules 13 and 14 are new; the others have been
reported previously.22,23
Modelling of CCP domain 4
The K224 deletion in the mutant Factor H protein is located
within the complement regulatory CCP 4 module and is
considered disease-relevant24–26 (Figure 4a and b). A structu-
ral model for the CCP 4 domain indicates that K224 is located
on a surface-exposed loop between the conserved b1 and b2
strands (Figure 4c). A sequence alignment of all known CCP
domain indicates that this loop corresponds to a variable
region, both in terms of amino-acid conservation and length.
The putative N-glycosylation site at Asn217 in CCP 4 lies
on the opposite side of the structure and will not affect
substrate binding (Figure 4c).
Characterization of functions associated with the C-terminal
recognition domain.
Factor H was purified from plasma of both patients and their
asymptomatic parents to homogeneity, and was used for
binding and functional analyses.
Heparin binding. Factor H purified from plasma of the
two patients and of their parents was bound to a heparin
matrix; individual elute fractions were generated, separated
by SDS-PAGE, and assayed by Western blotting (Figure 5a).
As identical conditions were used for chromatography, the
individual fractions can be compared directly. In all assays,
the elution profiles of Factor H were rather similar or almost
identical. Factor H derived from the two patients and their
mother showed peak elution in fractions 30–34. A slight shift
in the profile, that is, to fractions 32–36 was observed for
Factor H purified from the father and from a healthy control
person (Figure 5a and data not shown). On the basis of this
very similar elution profiles, we conclude that the mutation
in domain 4 does not interfere with heparin binding.
Patient A Father
Patient B Mother
222S  Q   K    I    I    Q K    I    I
Allele I:737 tct cag --- att att cag aag att att
Allele II:    tct cag --- att att cag --- att att
Figure 3 | Analysis of MPGN II associated Factor H gene
mutations. Sequence analysis of Factor H identified a mutation in
CCP 4 of the protein (deletion of three base pairs: cDNA 743–745),
resulting in a deletion of a Lys residue at position 224 (K224). Both
children are homozygous for the mutation and lack one single
amino-acid K224, which is located in CCP module 4. Both parents are
heterozygous for the mutation and have one defective and one intact
allele.
Table 2 | Factor H mutations identified in the two MPGN II patients and their healthy parents
Position Patient A Patient B Father Mother
Domain Gene cDNA Protein a b a b a b a b Comment
Promoter C30081T T T T T T T C T 22
CCP 4 D57967–57969 D743–745 K224del del del del del AAG del AAG del New mutation
(disease related)
CCP 5 C63488A C994A A307A C C C C C C A C Polymorphism22
CCP 7 C68401T C1277T H402Y T T T T T T C T Polymorphism23
Intron CCP 13–14 2487–28A/C A A A A A A C A New mutation
Factor H mutation(s) and polymorphisms identified in patients with MPGN II and in their parents. The individual columns labelled a and b represent the allelic forms. Based on
the profile in the two daughters, the allelic forms are identified in the genome of the mother.
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Figure 4 | Position of the identified mutation within the Factor H
protein. (a) Factor H is shown with the 20 complement control
protein modules, and the position of the deleted amino acid in
module 4 is highlighted. The position of the complement regulatory
region in the N-terminus and that of the recognition region in the
C-terminus are shown. (b) Schematic structure of CCP 4 of Factor H.
The Lys residue 224 is shown and highlighted with a purple circle.
This part of the loop is positioned in the outside region of the CCP
domain. (c) Ribbon view of the modelled CCP 4 of Factor H. In the
intact domain, the relevant Lys224 residue, denoted by a purple
sphere is positioned within a surface loop that is formed between
Cys-residue I and III. The b-strands are shown in green and the loops
connecting these are shown in blue. Two conserved disulphide
bridges are shown in orange. The N- and C-termini are denoted by
N and C, respectively.
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C3d binding. Binding of Factor H to immobilized C3d
was tested with purified proteins by surface plasmon
resonance. Binding to C3d is mediated by the C-terminal
recognition domain. The mutant protein was prepared from
plasma of both patients and the preparation obtained from
their parents that represent a mixture of mutant and wild-
type protein and also wild-type Factor H bound with similar
intensities (Figure 5b). Identical amounts of purified Factor
H were used in each assay (data not shown), thus the
mutation in domain 4 does not affect C3d binding.
Cell binding. Factor H purified from plasma of the two
patients or their parents showed comparable binding to
human umbilical vein endothelial cells. When assayed by flow
cytometry, the binding activity of the patients, their mother
and father were comparable and reached mean fluorescence
values of 161, 154, 191, and 164, respectively. Factor H
derived from a healthy individual showed very similar values
(mean fluorescence 12.8) (Figure 6a). In addition, binding
was confirmed on the single cell level by confocal microscopy
(Figure 6b). The patient derived Factor H, protein purified
from their parents, and wild-type Factor H showed identical
intensity of staining.
These results show that the mutant protein has intact
C-terminal recognition and cell-binding functions, that is,
heparin-, C3d binding, as well as cell binding.
Characterization of functions associated with the N-terminal
regulatory domain
The N-terminus of Factor H mediates complement regula-
tion and binds to C3b.
Binding to the central complement component C3b. Binding
of Factor H to immobilized C3b was tested by plasmon
resonance using identical amounts of purified protein.
Patient derived Factor H bound weakly as judged by the
low association as well as the disassociation profiles (Figure
7a). In contrast, proteins derived from the parents bound
strongly to C3b (Figure 7a), demonstrating that the mutation
in CCP 4 affects C3b binding.
Peptid spot assay. The linear C3b-binding region(s)
within the CCPs 1–4 of Factor H was assayed by peptide
spot assays. Following incubation with C3b, three distinct
binding regions located in CCP 2, CCP 3, and CCP 4 were
identified, which are positioned within the loop formed
between Cys I and III. The first binding site is formed by
residues 103–124 and the second by residues 166–184. The
third region in CCP 4 ranges from position 223 to 238
(Figure 7b) and includes K224 (circle).
Fraction no. 24
Patient A
Patient B
Mother
Father
4038363432302826
Patient A
Patient B
Mother
Father
300
200
100
0 200 400 600 800 1000
Time (s)
R
es
on
an
ce
 u
ni
ts
a
b
Figure 5 | C-terminal heparin and C3d binding of Factor HD224.
(a) Heparin affinity of Factor H purified from plasma of the two
patients who are homozygous for the K224 mutation and from their
heterozygous parents. After loading plasma to heparin, the matrix
was washed thoroughly and bound proteins were eluted using a
linear NaCl gradient. Elution was performed under identical
conditions. Individual fractions were collected, separated by
SDS-PAGE and analyzed by Western blotting. Fractions representing
the peak protein concentration are boxed. (b) Binding to C3d.
Binding of purified mutant Factor H derived from the two patients
and Factor H derived from their parents to the immobilized C3
degradation product C3d was analyzed by surface plasmon
resonance. Factor HD224 (10 mg) purified from the two homozygous
patients and a mixture representing (Factor HD224 /Factor Hwt) from
their heterozygous parents was injected into a flow cell to which C3d
was immobilized. The profile obtained in the control flow cell
was subtracted.
Patient A Mother
104103102101100
FL1-H
Co
un
ts
0
10
20
30
40
50
60
70a
b
Figure 6 | C-terminal cell binding of Factor HD224. (a) Flow
cytometry. Patient-derived mutant Factor HD224 (homozygous
preparation) and proteins derived from their heterozygous parents
were tested for binding to human umbilical vein endothelial cells
cultivated in the absence of serum. (b) Confocal microscopy. Staining
of human umbilical vein endothelial cells incubated with Factor H
purified from patient A or the mother. Factor H binding was
visualized with a rabbit CCPs 1–4 antiserum and a secondary goat
anti-rabbit antiserum labelled with Alexa 488 for green fluorescence.
Protein purified from the two patients, their parents, and wild-type
Factor H showed the same intensity of binding (data not shown).
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Complement regulatory activity
Cofactor activity of purified Factor H was assayed and
cleavage of C3b was followed by the appearance of the 43 kDa
cleavage product of the alpha chain of C3. Factor H derived
from the two patients showed severely reduced cofactor
activity (Figure 8a, lanes 1 and 2). In contrast, protein
prepared from the parents showed normal cofactor activity,
which was comparable to the wild-type protein (Figure 8a,
lanes 3 and 4, and data not shown). A longer exposure of the
same blot revealed residual cofactor activity of the mutant
protein (Factor HDK224), which was about 10% of that of the
wild-type protein (data not shown). Thus, Factor HDK224
displays a strongly reduced, but still existing cofactor activity.
Decay-accelerating activity of purified Factor H protein
was tested with plasma of the patients and their parents
adjusted to equal concentrations of Factor H. Plasma of the
two patients showed strong lysis of sheep red blood cells
(patient A: 83%; patient B: 71%) revealing a defective
dissociation activity. Plasma of the parents showed owing to
Factor H mediated decay activity low levels of lysis (i.e. 37%).
This activity was comparable to control plasma (36–40%).
The increased lysis obtained with the patient plasma show a
defective regulatory function of mutant Factor H (Figure 8b
and Table 1).
DISCUSSION
We report a potentially novel pathomechanism for MPGN II.
To our knowledge, we characterize the first mutant Factor H
protein that is expressed in plasma but lacks complement
regulatory activities. So far the absence of Factor H in
plasma, functional inactivation of Factor H by an autoanti-
body, or stabilization of the C3 convertase by C3NeF have
been reported as a cause of MPGN II.
Activation of the alternative pathway of complement
occurs spontaneously and results in continuous, low-level
generation of the convertase C3bBb.27 This enzyme repre-
sents a central check point for complement activation and its
activity and stability is tightly controlled. The complement
inhibitor Factor H in combination with Factor I control the
stability of this convertase, which is relatively unstable and
shows a half-life of about 4 min in vitro. Three distinct
scenarios stabilize the convertase C3bBb: (i) the absence of
Factor H in plasma, (ii) the presence of a circulating Factor H
inhibitor, or (iii) the presence of the autoantibody
C3NeF.13–15 Each scenario independently increases C3b
turnover and causes hypocomplementemia. As a conse-
quence, complement activation proceeds in fluid phase and
at particular sites, that is, tissue surfaces that lack endogenous
regulators. The glomerular basement membrane of the
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Figure 7 | N-terminal C3b binding activity of Factor HD224.
(a) Binding to the central complement component C3b. Binding of
purified mutant Factor H derived from the two patients and Factor H
derived from their parents to immobilized C3b was analyzed by
surface plasmon resonance. Factor HD224 (10 mg) purified from the
two homozygous patients and a mixture representing (Factor HD224/
Factor Hwt) form their heterozygous parents were injected into a flow
cell. The profile obtained in the control flow cell was subtracted.
(b) Linear binding motifs in the N-terminus of Factor H for C3b.
Peptides with a length of 13 amino acids, which cover the complete
N-terminus of Factor H (i.e. CCPs 1–4) were spotted onto membranes
and binding of C3b was analyzed. The three binding regions in CCP 2,
CCP 3, and CCP 4 in the peptide spot (upper panel) are circled and in
the amino-acid sequence (lower panel) are shown in inverted
characters. The deleted K224 positioned in the N-terminal domain of
the third C3b-binding region in module 4 is circled. The conserved
cysteine residues are highlighted in gray.
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Figure 8 | N-terminal regulatory activities of Factor HD224.
(a) Cofactor activity of Factor H purified from the two patients and
their parents was tested in fluid phase. Factor H, purified Factor I,
and C3b were incubated for 30 min, the proteins were separated by
SDS-PAGE, transferred onto a membrane by electroblotting, and
detected by Western blot using a C3-specific antiserum. Cofactor
activity is confirmed by the appearance of the 43 kDa a0 C3 chain.
A longer exposure of the same blot shows residual cofactor activity of
the mutated protein derived from plasma of the two patients (data
not shown). Densitometric evaluation showed that this residual
activity was about 10% of that of the wild-type protein (data not
shown). (b) Decay-accelerating activity. An active alternative pathway
convertase C3bBb was assembled on the surface of sheep red blood
cells, plasma of the patients and their parents was added, and
hemolysis was recorded. Plasma derived from both patients showed
strong lysis of sheep erythrocytes (i.e. patient A: 83 and patient B:
71%). In contrast, plasma of the father and the mother (both 37%)
and that of healthy controls showed low level lysis owing to intact
ability of the Factor H to dissociate the convertase (cofactor activity)
(36–40%). A representative result of three independent experiments
is shown.
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kidney represents such a sensitive surface and requires the
soluble immune inhibitor Factor H for protection. Lack or
functional inactivation of Factor H results in continuous C3
deposition and formation of ‘dense deposits’ within the
glomerular basement membrane (MPGN II). As a conse-
quence, the glomerular basement membrane thickens, which
impairs filter function, causes hematuria and proteinuria,
and eventually results in progressive loss of renal function.
Factor H has two functional domains, which are posi-
tioned at the opposite ends of the protein. The N-terminus,
with CCPs 1–4, includes the regulatory domain that is
responsible for complement regulation, that is, cofactor
and decay-accelerating activity, as well as binding to the
central component C3b. The C-terminus, that is, CCPs 19
and 20 mediates recognition of ligands and binds to
heparin, C3d, and to cell surfaces.28 The single amino acid
deletion DK224 within CCP 4 affects the regulatory
functions, but the recognition functions and cell-binding
activity remain intact (Figures 7 and 8). Intact recognition
functions are demonstrated by normal heparin-, C3d-, and
cell-binding activities (Figures 5 and 6). However, the
N-terminal activities, that is, C3b binding and complement
regulation of Factor HDK224 are defective (Figures 5–7).
Structural modelling revealed that the deleted residue is
located in a surface-exposed loop (Figure 4). CCP 1 of
CD46,29 and CCP 1 as well as CCP 3 of human b2-glyco-
protein I30 also have a Lys residue at this position and the
crystal structures show that these Lys residues are surface-
exposed. Peptide spot analyses localize the deleted Lys residue
within a linear C3b-binding region (Figure 7b). The loss of
K224 may change the orientation and folding of this C3b-
binding region, thus leading to defective substrate binding.
The two MPGN II patients express a mutant Factor H
protein, and are also positive for C3NeF. Initially, the
presence of C3NeF was considered disease-relevant. However,
as the mother who was also positive for C3NeF showed no
signs of kidney disease, we initiated genetic analyses. As the
purified mutant Factor H protein shows defective comple-
ment regulatory functions, the deletion of K224 is considered
relevant for MPGN II. In our view, this concept is supported
by the fact that the C3NeF positive healthy mother, who is
heterozygous for this mutation does not show signs of kidney
damage. C3NeF is an auto-antibody of the IgG or
immunoglobulin M class, which binds a neoepitope of the
alternative pathway convertase C3bBb. C3NeF stabilizes the
active enzyme complex and increases half-life of the
convertase by approximately 10-fold.13 The autoantibody
C3NeF is associated with MPGN II and present in a high
percentage of MPGN II patients. However, C3NeF is not a
specific marker for MPGN II. Similar to the healthy mother,
other healthy nonaffected individuals are tested positive for
C3NeF.15,20 However, combination of two separate scenarios,
for example, Factor H mutation and the presence of C3NeF,
stabilize the C3bBb convertase more efficiently, thus increas-
ing the damaging potential of the unrestrictedly activated
alternative complement pathway.
Thus, it is not only the concentration but also the
functional activity of circulating Factor H protein, which is
associated with/relevant for MPGN. In conclusion, either the
absence or defective function of circulating Factor H protein
causes MPGN.
The residual complement regulatory activity of mutant
Factor H protein might influence the severity of kidney
damage. Owing to this residual activity, disease progression is
possibly slower as in patients who completely lack Factor H.
The residual regulatory activity of mutant Factor H might
limit complement activation (C3 deposition, etc) at the
glomerular basement membrane, which possibly explains
why with 11 and 6 years of age the two patients are older than
Factor H deficient patients, who develop MPGN II much
earlier in life (at about 12–18 months of age).11,18
On the basis of identified defect, patients were treated with
infusions of fresh frozen plasma in order to substitute for
functionally intact Factor H. Infusions were given regularly
every 14 days. The treatment interval was derived from
measured half-life of Factor H of about 6 days.31 In
accordance with the literature, we infused 10–15 ml fresh
frozen plasma per kg body weight within about 3 h.32 Except
for one episode with mild hypotension in patient A, and a
few episodes with unspecific abdominal pain in patient B,
which were interpreted as symptoms of mild allergic
reactions and could be treated by temporary discontinuation
of fresh frozen plasma infusion and administration of a
histamine antagonist, the treatment was well tolerated and
kidney function so far remained normal in both patients.
In summary, impaired function of complement regulator
Factor H seems to be relevant for the development of MPGN
II. Disease occurs as a result of unrestricted activation of the
alternative complement pathway mediated by the alternative
pathway C3 convertase C3bBb. Loss of the function of two
components of the control system for C3bBb activity – defect
function of Factor H plus the presence of C3NeF – definitely
pushes the balance of activation/inactivation of the alter-
native pathway towards activation. The presence of C3NeF
alone is obviously – at least in the present reported patients –
not sufficient as disease-causing factor.
As a consequence, detailed analysis of the complement
system including C3NeF and Factor H – concentration and
function – is required for the diagnosis of MPGN II in the
future.
MATERIALS AND METHODS
Patients
The two patients, a 6 and an 11-year-old girl, are daughters of
healthy consanguineous (first grade cousins) Turkish parents. The
older girl (patient A) developed microhematuria and mild
proteinuria at 5 years of age. Clinical examination, ultrasound of
the kidney, and basic laboratory parameters (including serum
creatinine, blood urea nitrogen, and serum albumin) were normal.
Renal biopsies of the two patients (patient A at 5 and 10, patient B at
5 years of age) showed typical histological findings of MPGN II with
dense deposits within the glomerular basement membrane. C3c
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deposition along the glomerular basement membrane was detected
by means of immunohistology. The younger girl (patient B)
developed identical clinical symptoms; however, the onset of disease
occurred during the first months of life. Renal biopsy (at 5 years of
age) confirmed the suspected diagnosis, ‘dense deposit disease’.
Other factors causing hematuria and proteinuria were excluded in
both patients. Informed consent for participation in this study was
obtained from the patients and their parents.
Complement analysis
Functional activity of alternative (APH50) and classical (CH50)
complement pathway was measured in hemolytic assays.33,34 Plasma
concentrations of C3 and Factor B were determined by radial
immunodiffusion or nephelometry.20 C3dg/C3d was measured by
double-decker rocket immunoelectrophoresis, using rabbit anti-C3c
antibodies in the lower and rabbit anti-C3d antibodies (Dako,
Hamburg, Germany) in the upper gel.
Plasma concentrations of complement Factor H were assessed by
enzyme-linked immunosorbent assay using polyclonal goat anti-
human Factor H IgG, (Quidel, San Diego, CA, USA) as capture
antibody.35 Bound Factor H molecules were detected by a
monoclonal mouse anti-human Factor H IgG (Serotec, Oxford,
UK). The reactions were visualized by the appropriate peroxidase-
conjugated third antibody, using 2,20-azino-bis-3-ethyl-benzothia-
zoline sulfonate (ABTS)/H2O2 as substrate. Optical density was
measured at 405 nm on an EAR 340 AT Microplate Reader (SLT,
Calbiochem, Germany). Purified Factor H (Calbiochem) was used
as standard.
C3 nephritic factor
Activity was assessed using a hemolytic assay described previously.36
Factor I
Plasma concentrations were assessed by enzyme-linked immuno-
sorbent assay as previously described.37 Monoclonal anti-human
factor I IgG (Genzyme, Boston, USA) was used as capture antibody
and Factor I was detected using goat anti-I IgG (ICN, Bonn,
Germany). The reactions were visualized by the appropriate
peroxidase-conjugated third antibody. Purified Factor I (Quidel,
San Diego, CA, USA) was used as standard.
Western blot of plasma factor H
Plasma of the two patients, their parents, and a healthy control
person was separated by SDS-PAGE, transferred onto a membrane,
and developed with specific Factor H antibodies.38
Isolation of genomic DNA and sequence analysis
Blood of the two patients and their parents was collected and
genomic DNA was isolated, according to the instructions of the
manufacturer. Specific DNA fragments were amplified by PCR using
exon specific primers22 and applied for sequence analysis with an
ABI 370 sequence analyser. The sequences were compared to that of
the genomic or cDNA clone.
Purification of plasma factor H
About 3 ml plasma derived from the two patients, their parents, and
a healthy control person were used for Factor H purification. Plasma
was precipitated with 13% PEG 6000 (polyethylenglycol, MW
6000 Da) on ice. The pellet was dissolved in 1 ml buffer A (10 mM
sodiumphosphate, 0.1 M glycine, pH 7.3) and applied to heparin
affinity chromatography using a 1 ml HiTrap heparin column and
the AKTAPrime system (GE Health Care, Freiburg, Germany).39 The
bound material was extensively washed with buffer A and eluted
with a linear salt gradient, ranging from 30 to 500 mM NaCl in a
total volume of 30 ml. Individual fractions of 400 ml were collected
and Factor H containing fractions were combined. After dilution in
deionized water, the solution was subjected to ion exchange
chromatography on a 1 ml Resource Q column (GE Health Care)
in buffer A. Bound proteins were eluted by using a linear gradient
ranging from 30 to 500 mM NaCl in a total volume of 30 ml.
Fractions containing Factor H were combined and concentrated
using Ultrafree-Centrifugal devices (Millipore Corp., Bedford, MA
USA). The purified Factor H preparation contained no additional
contaminating bands as assayed upon SDS-PAGE in combination
with silver staining. In addition, the preparation was negative for C3,
Factor I, and FHL-1 as tested by Western blotting.
The concentration of the purified Factor H fractions was
confirmed by Bradford assay, silver staining following SDS-PAGE
separation and by enzyme-linked immunosorbent assay35 (data not
shown). Equal amounts of purified Factor H were used for
functional assays.
Cell-binding assays
Human umbilical vein endothelial cells were cultivated as
described.39 Cells were incubated with equal concentrations of
Factor H (2 mg) purified either from plasma of the patients, their
parents, or a normal control. Following incubation with a Factor H
antiserum, a secondary FITC labelled anti-goat antiserum was
added. The cells were processed by flow cytometry using an FACS
calibur (Becton and Dickinson, Heidelberg, Germany) or by
confocal microscopy.39
Surface plasmon resonance
Identical amounts of Factor H purified from plasma of the two
patients and their parents were applied to immobilized C3b and C3d
using a Biacore 3000 instrument.40 Briefly, C3b or C3d was
immobilized via standard amine coupling to the flow cells of a
sensor chip (Carboxylated dextran chip CM5, Biacore, AB, Uppsala,
Sweden). After coupling, flow cells were washed thoroughly by
sequential injection of regeneration buffer (2 M NaCl in 10 mM
acetate buffer, pH 4.6) and running buffer (0.5 phosphate-
buffered saline, pH 7.4). Binding of Factor H purified from the two
patients and their parents was tested. Binding experiments were
performed at least three times.
Cofactor assay
C3b was mixed with 1 mg Factor I and 10 mg of purified patient-
derived Factor H for 30 min at 371C and separated by SDS-PAGE as
described.41 The proteins were transferred by electro blotting, and
the nitrocellulose membrane was developed with a polyclonal anti-
C3b serum (Calbiochem) by enhanced chemiluminescence (GE
Health Care). Quantitative analysis was performed after a second
incubation of the same filter with Alexa 488 labelled C3b antiserum
(Alexa 488, Molecular Probes, Eugene, OR, USA), using a
fluorescence scanner (Typhoon, GE Health Care).
Decay-accelerating activity
Decay-accelerating activity was measured by hemolytic assay. In
brief, an alternative pathway C3 convertase was generated with
EAC4bC3b, using optimal amounts of purified Factor B, Factor D,
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and properdin. EAC4bC3bBbP was then exposed to serum derived
from the patients, their parents, or normal serum as source of Factor
H or purified Factor H in idealization buffer GVBS-ethylenediamine-
tetraacetate as control. After 15, 30, and 60 min incubation at 37oC,
rat serum was added to allow formation of the lytic C5b-9 complex
and lysis of the erythrocytes was measured at 412 nm.
Homology modelling of the CCP 4 domain of Factor H
To model CCP 4, suitable CCP domain templates were identified
with PSI-BLAST searches of the Protein Data Bank using the
PredictProtein Server (http://cubic.bioc.columbia.edu/predictpro-
tein/), and the Pfam Database42 to identify CCP domains within
Protein Data Bank structures. The sequences of these structures were
then used to produce CLUSTALW multiple sequence alignments
with the sequence of CCP 4, in which the templates with the closest
sequence similarities to CCP 4 were identified.43 The closest
template was identified as CCP 16 of factor H (Protein Data Bank
code 1hcc)44 with the model only requiring a one-residue deletion in
a structurally variable region of the 1hcc template. The DSSP
program45 was used to assign the secondary structure. The CCP 4
domain was modelled using INSIGHT II 98.0 software (Accelrys,
San Diego, CA, USA) on a Silicon Graphics workstation. The
structurally conserved regions were built using a rigid body
fragment assembly method. The one-residue deletion between
Ser222 and Gln223 was incorporated within a two-residue loop
taken from the loop database of INSIGHT II. Energy minimization
refined the connectivity of the loop splice junctions and the loop
itself, and the final model was checked using the structure
verification program PROCHECK46 and the structure idealization
program REFMAC5 of CCP 4i.47
Peptide spot analysis
Peptides representing the N-terminus of Factor H (i.e. CCPs 1–4),
having a length of 13 amino acids and an overlap of 10 amino acids
were synthesized and coupled to a cellulose membrane (Jerini,
Berlin) and treated as described.48
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